Navigation Links
Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society

- Co-Injection of rHuPH20 with Humira Estimated to Increase the Maximal Steady State Subcutaneous Bioavailability from 64% to 100% -

SAN DIEGO, July 09, 2007 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that final results of the Enhanze(TM) Technology clinical trial demonstrating improved absorption and bioavailability of a representative commercially-available large protein molecule therapeutic (LPMT) were presented at the 34th Annual Meeting of the Controlled Release Society in Long Beach, California. Enhanze Technology is Halozyme's enzyme-based drug delivery platform based on recombinant human PH20 hyaluronidase (rHuPH20). The abstract describing this trial was rated by the Controlled Release Society as having notable high scientific quality and was designated for a podium presentation, which included a recently completed modeled population pharmacokinetic (PK) analysis used to estimate the effect of steady state co-administration of rHuPH20 with the LPMT.

This clinical trial, sponsored and funded solely by Halozyme, compared the PK, safety, and tolerability of an LPMT agent subcutaneously (SC) injected first without Enhanze Technology (rHuPH20) and then with rHuPH20 in 15 patients. The representative LPMT selected for this trial was HUMIRA(R) (adalimumab), based on the product being readily commercially available, well-recognized, labeled for SC route of administration, and for which a validated assay for PK profiling could be developed. The open-label cross-over study used escalating doses of rHuPH20 (ranging from 1,600 U to 12,800 U) and a fixed dose of HUMIRA (40 mg) injected every two weeks. Patients with rheumatoid arthritis on maintenance HUMIRA were crossed-over to a single SC injection of HUMIRA co-injected with rHuPH20, and the two injections were compared with regard to PK and s
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
2. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
3. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
4. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
5. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
6. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
7. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
10. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
11. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
Post Your Comments:
(Date:5/22/2013)... , 22. Mai 2013  Grifols, ein ... Barcelona , Spanien, präsentierte ... eine höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) ... Alpha1-Antitrypsinmangel (AAT) auf ein Niveau anhebt, das ... Bereichs liegt. ATT-Mangel ist eine lebensbedrohliche, genetische ...
(Date:5/22/2013)... Israel , May 22, 2013  Rosetta ... developer and provider of microRNA-based molecular diagnostics, announces that ... Chief Executive Officer of Rosetta Genomics, will deliver a ... place from June 3-6, 2013 in New York City.  ... 4 th at 2:00 p.m. Eastern time. ...
(Date:5/22/2013)... , May 22, 2013  Medifocus, Inc. (OTCQX: MDFZF and ... , Chief Operating Officer, will present at the Second Annual ... New York City at the Grand ... to begin at 4:00 p.m. EDT and will be available ...   http://wsw.com/webcast/marcum/mfs.v/   For more information and registration, ...
Breaking Medicine Technology:Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3
... CLEVELAND, Dec. 1, 2011  NDI, a leading venture capital ... office, a third major location in addition to its ... The Minneapolis office will be run by medical device ... for Market Development. (Photo: ...
... Company (NYSE: LLY ) has been named one of ... partnership with FORTUNE and the RBL Group. Lilly ranked 16th on ... The survey is one of the most comprehensive studies ... Companies first complete an extensive survey, and senior executives from ...
Cached Medicine Technology:NDI Brings on Industry Veteran Mark Stultz to Head Up New Minneapolis Office 2Eli Lilly and Company Named a Top Global Company for Leaders 2
(Date:5/22/2013)... new study suggests that disturbed sleep in adolescents ... greater uncertainly about future success. However, perceived ... to have a protective effect. , Results ... depressed mood and greater uncertainty about future success. ... from teachers were associated with significantly fewer sleep ...
(Date:5/22/2013)... Auburn, AL (PRWEB) May 22, 2013 ... Jr. of Birmingham, Alabama. A University of Alabama graduate, ... its surrounding areas. As a TeethWhiteningforFree.com dentist, he extends ... office for a routine exam and/or check up. Only ... health makes them eligible for whitening treatments. ...
(Date:5/22/2013)... With the health of a growing fetus largely dependent ... that many women become hyperaware of everything that goes into ... on a pregnancy test. At no other time in life ... (like caffeine, alcohol, and nicotine) stronger than during pregnancy. But ... Does this increased awareness during pregnancy extend to the lotions, ...
(Date:5/22/2013)... Peak Solar introduces unique, interactive solar training seminars, which ... make informed buying choices. Research studies tell companies that ... to give them the tools needed to make informed ... Solar training seminars will be introduced onto the website, ... kits . , Poised to help both residential and ...
(Date:5/22/2013)... CA (PRWEB) May 22, 2013 Many problems ... great deal of pain for a patient if left untreated. ... their pain could be easily fixed through occlusal adjustment. ... or neck and back pain should have their dentist check ... change the bite and can lead to problems if the ...
Breaking Medicine News(10 mins):Health News:Parent and teacher support protects teens from sleep problems and depression 2Health News:Dr. James Sanderson, Jr. Of SanDentistry in Hoover, Alabama Joins the TeethWhiteningforFree.com Family 2Health News:Fairhaven Health Launches New PregnancyPlus Natural Deodorant Designed Specifically for Pregnant Women 2Health News:Online Solar Training Seminars Aimed at Informing Consumers 2Health News:Dr. Martin N. Gorman: Make Headaches, Sensitive Teeth and Neck or Back Pain a Thing of the Past 2
... people with no history of mental illness feel suicidal. Prozac ... has been one of the pharmaceutical industries biggest success stories ... of drugs known as SSRIs (selective serotonin reuptake inhibitors). This ... were hailed as "wonder drugs" when they first hit the ...
... both in the USA and all over the world. The drug ... long-term. It raises the risk of high blood pressure, diabetes, cancer ... long term, and there has seen to be a need, now, ... Harvard University in the USA have discovered that the drug bupropion, ...
... Inhaling too much cocaine is well known to cause damage ... it can force the body to attack itself.New Scientist reports ... hospitals with cocaine related emergencies has jumped from around 80,000 ... ,Working on rabbit hearts, a University of Michigan team have ...
... a twin study reveals that cholesterol levels are controlled ... blood cholesterol are often advised to go on a ... known that reducing fat intake can reduce cholesterol levels. ... hypercholesterolaemia (FH) which leads to high cholesterol.// People with ...
... are trialling the first long-acting male contraceptive which stops the ... is a combination of hormones. ,In the trial, men ... of the male hormone testosterone is placed under the skin ... Kings Hospital in UK says the technique works by putting ...
... Healthcare announced a strategic alliance with Mumbai-based Kopran ... collaborative research while taking over the Kopran's anti-hypertensive ... is the largest brand in the cardiovascular segment. ... Pharma brands. // , As a ...
Cached Medicine News:Health News:Wonder drug - could end in disaster 2
Shake 'n' Stack Oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual PLUS Shaker Platform)...
Inquire...
... Hybridization Oven / Shaker : Temperature ... platform for the hybridization and incubation of ... be used for gel processing and staining. ... volumes to be used providing enhanced sensitivity ...
... Bio-Dot and Bio-Dot SF (slot format) microfiltration ... protein or nucleic acid in solution onto ... can be accommodated by using interchangeable templates ... 48-well slot format Bio-Dot SF apparatus. Each ...
Medicine Products: